China000590.CS▼
Guhan Pharmaceutical expects net loss attributable to parent of 13 million to 18 million yuan in first half of 2026
Guhan Pharmaceutical disclosed its earnings forecast, expecting a net loss attributable to the parent of 13 million to 18 million yuan in the first half of 2026, compared with a loss of 17.1701 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 15 million to 21 million yuan, compared with a loss of 22.6522 million yuan in the same period last year. The main reason for the loss is the impact of the centralized drug procurement policy, which has led to a continued decline in sales revenue of the core product Yixinshu Tablets of its wholly-owned subsidiary Guhan Guangdong Pharmaceutical Company Limited, resulting in an expanded loss for the subsidiary. In addition, in the same period last year, the company received a reversal of credit impairment losses of about 6 million yuan from the original shareholders' performance compensation, and there is no such income in this period.